GlassScriptPhysician profile
Courtney W Hatcher
NPI 1861849697
$1,990.39
in general payments reported to CMS, 2019-2025
27 companies · $684 in 2025
The $684 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $165 · 2021: $254 · 2022: $137 · 2023: $70.04 · 2024: $519 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $390.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $319.47 | 2022-2025 | |
| Lilly USA, LLC | $209.55 | 2019-2024 | Mounjaro |
| Amgen INC. | $143.81 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbott Laboratories | $115.88 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Dexcom, INC. | $115.03 | 2024-2025 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $90.56 | 2024-2025 | Apretude |
| Abbvie INC. | $87.00 | 2025 | |
| Dynavax Technologies Corporation | $80.32 | 2021-2022 | |
| Exact Sciences Corporation | $61.85 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $56.78 | 2020-2025 | Airsupra |
| Sanofi Pasteur INC. | $43.24 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $32.99 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.80 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.28 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $20.48 | 2024 | Inspire |
| Gilead Sciences, INC. | $19.64 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.18 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.42 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2025 | Jardiance |
| Astellas Pharma US INC | $17.14 | 2021 | |
| Daiichi Sankyo INC. | $16.00 | 2019 | |
| Amarin Pharma, INC. | $13.64 | 2019 | |
| Pulmonx Corporation | $13.34 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Janssen Pharmaceuticals, INC | $12.17 | 2019 | |
| Ibsa Pharma INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Hatcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.